Physician profile
Robert Thomas Light
NPI 1881677391
$2,374.44
in general payments reported to CMS, 2019-2025
15 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $266 · 2021: $275 · 2022: $362 · 2023: $327 · 2024: $367 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $632.56 | 2019-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $473.70 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $362.65 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $264.57 | 2020-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $254.32 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $86.08 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $51.84 | 2021-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $46.95 | 2019 | |
| Indivior INC. | $43.64 | 2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.66 | 2020-2021 | |
| Bioxcel Therapeutics, INC. | $34.89 | 2023 | Igalmi |
| Lundbeck LLC | $32.58 | 2019-2020 | |
| Almatica Pharma LLC | $29.08 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $12.84 | 2019 | |
| Allergan, INC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Light listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.